Close collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue 8, 2011, Pages 999-1004

  Eichler, I ^a   Soriano, E Sala ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

allergens; allergic rhinitis; children; specific immunotherapy

Indexed keywords

ALLERGEN;

ALLERGIC DISEASE; DISEASE COURSE; EVIDENCE BASED PRACTICE; GERMANY; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MOTIVATION; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY TRACT DISEASE; REVIEW;

ACADEMIC MEDICAL CENTERS; ALLERGENS; CHILD; COOPERATIVE BEHAVIOR; DESENSITIZATION, IMMUNOLOGIC; DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 79959941024     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02582.x     Document Type: Review

References (42)

1. Bjorksten B, Clayton T, Ellwood P, Stewart A, Strachan D,; ISAAC Phase III Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008; 19: 110-124. (Pubitemid 351197288)
2. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al., Burden of allergic rhinitis: results from the pediatric allergies in America survey. J Allergy Clin Immunol 2009; 124 (3 Suppl.): S43-S70.
3. Strachan D, Sibbald B, Weiland S, AÃt-Khaled N, Anabwani G, Anderson HR, et al., Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997; 8: 161-176. (Pubitemid 28127720)
4. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al., Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN* and AllerGen**). Allergy 2008; 63 (Suppl. 86): 8-160. (Pubitemid 351357811)
5. Des Roches A, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J,. Immunotherapy with a standardized Dermatophagoides pteroyssinus extract, VI: specific immunotherapy prevents the onset of new sensitisations in children. J Allergy Clin Immunol 1997; 99: 450-453. (Pubitemid 27173080)
6. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, HÃst A, et al., Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-948. (Pubitemid 47037870)
7. Noon L,. Prophylactic inoculation against hay fever. Lancet 1911; 1: 1572-1573.
8. Freeman J, Noon L,. Further observation on the treatment of hay-fever by hypodermic inoculation of pollen vaccine. Lancet 1911; 2: 814-817.
9. Durham SR, Leung DYM,. One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol 2011; 127: 3-7.
10. Directive 2001/83/EC of The European Parliament and of The Council of 6 November 2001 on The Community Code Relating to Medicinal Products for Human Use. Official Journal L-311, 28/11/2004, pp. 67-122. Available at
11. The Council of the European Communities. Directive 89/342/EEC extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergens. Official Journal 1989; L142: 14-15.
12. Cox L, Jacobsen L,. Comparison of allergen immunotherapy practice patterns in the Unites States and Europe. Ann Allergy Asthma Immunol 2009; 103: 451-459.
13. Gödicke V, Hundt F,. Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline. Allergy 2010; 65: 1499-1505.
14. Calderõn MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P,. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127: 30-38.
15. US Food and Drug Administration, Center for Biologics Evaluation and Research. Allergenics. Available at
16. Cox L, Compalati E, Canonica W,. Will sublingual immunotherapy become an approved treatment method in the United States? Curr Allergy Asthma Rep 2011; 11: 4-6.
17. ICH Harmonised Tripartite Guideline. Clinical investigation of medicinal products in the pediatric population. ICH Topic E11. Available at
18. US Food and Drug Administration, Pediatric Drug Development. The Pediatric Research Equity Act of 2007 (PREA) and Best Pharmaceuticals for Children Act of 2007 (BPCA). Available at
19. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal L -378, 27/12/2006, pp. 1-18. Available at
20. Verordnung über die Ausdehnung der Vorschriften über die Zulassung der Arzneimittel auf Therapieallergene, die für einzelne Personen auf Grund einer Rezeptur hergestellt werden, sowie über Verfahrensregelungen der staatlichen Chargenprüfung (Therapieallergene- Verordnung) Bundesgesetzblatt Jahrgang 2008 Teil I Nr. 51, 2177-2178.
21. May S, Kaul S, Lüttkopf D, Vieths S,. Regulation, role and future of name patient products in Germany. Arbeiten aus dem Paul-Ehrlich Institut 2009; 96: 193-197.
22. Kaul S, Englert L, May S, Vieths S,. Regulatory aspects of specific immunotherapy in Europe. Curr Opin Allergy Clin Immunol 2010; 10: 594-602.
23. Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/2007. Available at
24. EMA/PDCO Standard paediatric investigation plan for allergen products for specific immunotherapy. Available at
25. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases (CHMP/EWP/18504/2006). Available at
26. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al., Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64 (Suppl. 91): 1-59.
27. Larenas-Linnemann D,. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol 2009; 9: 168-176.
28. Halken S, Lau S, Valovirta E,. New visions in specific immunotherapy in children: an iPAC summary and future trends. Pediatr Allergy Immunol 2008; 19 (Suppl. 19): 60-70.
29. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al., Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62: 317-324.
30. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR,. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998; 101: 163-170. (Pubitemid 28152377)
31. Juniper EF, Guyatt GH, Dolovich J,. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93: 413-423. (Pubitemid 24081781)
32. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HG,. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61: 198-201. (Pubitemid 43381830)
33. Canonica GW, Passalacqua G,. Disease-modifying effect and economic implications of sublingual immunotherapy. J Allergy Clin Immunol 2011; 127: 44-45.
34. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G,. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010; 126: 969-975.
35. Calderon M, Mösges R, Hellmich M, Demoly P,. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 2010; 65: 420-434.
36. Adkins B,. Developmental immunity: impact on neonatal and childhood mucosal responses. Neonatal T cell function. J Pediatr Gastroenterol Nutr 2005; 40: S5-S7. (Pubitemid 40478389)
37. Klassen TP, Hartling L, Hamm M, van der Lee JH, Ursum J, Offringa M,. Starchild health: an initiative for RCTs in children. Lancet 2009; 374: 1310-1312.
38. Röder E, Berger MY, De Groot H, Van Wijk RG,. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 2008; 19: 197-207. (Pubitemid 351499173)
39. Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS, et al,. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009; 124: 665-670.
40. Clinical Trials Directive (2001/20/EC). Directive of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Available at
41. Smyth R, Weindling AM,. Research in children: ethical and scientific aspects. Lancet 1999; 354 (Suppl. 2): SII21-24.
42. European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Available at